Humanized antibodies with increased stability
US11066470B2 · kind B2 · utility
2Cited by
10References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2019 |
| Grant date | Jul 20, 2021 |
| Priority date | — |
| Expiry date | Aug 21, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.